ARTICLE | Company News
Cureveda, NIH autoimmune news
July 29, 2013 7:00 AM UTC
Cureveda received a Phase I Small Business Innovation Research (SBIR) grant totaling $150,000 from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases to develop VEDA-1209 to treat ulcerative colitis (UC). The small molecule nuclear factor (erythroid-derived 2)-like 2 ( NFE2L2; NRF2) activator is in preclinical development. Cureveda said it hopes to start Phase I testing in about 18 months. ...